Publicaciones (80) Publicaciones de BEATRIZ SUAREZ ALVAREZ

2024

  1. BET inhibitor nanotherapy halts kidney damage and reduces chronic kidney disease progression after ischemia-reperfusion injury

    Biomedicine and Pharmacotherapy, Vol. 174

  2. Inhibition of BRD4 Attenuates ER Stress-induced Renal Ischemic-Reperfusion Injury

    International Journal of Biological Sciences, Vol. 20, Núm. 5, pp. 1547-1562

2023

  1. BET Protein Inhibitor JQ1 Modulates Mitochondrial Dysfunction and Oxidative Stress Induced by Chronic Kidney Disease

    Antioxidants, Vol. 12, Núm. 5

  2. The transcription factor Fosl1 preserves Klotho expression and protects from acute kidney injury

    Kidney International, Vol. 103, Núm. 4, pp. 686-701

  3. Type IV Collagen and SOX9 Are Molecular Targets of BET Inhibition in Experimental Glomerulosclerosis

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2022

  1. Ccn2 increases tgf‐β receptor type ii expression in vascular smooth muscle cells: Essential role of ccn2 in the tgf‐β pathway regulation

    International Journal of Molecular Sciences, Vol. 23, Núm. 1

  2. Demethylation of H3K9 and H3K27 Contributes to the Tubular Renal Damage Triggered by Endoplasmic Reticulum Stress

    Antioxidants, Vol. 11, Núm. 7

  3. Divergent SARS-CoV-2-specific T cell responses in intensive care unit workers following mRNA COVID-19 vaccination

    Frontiers in Immunology, Vol. 13

  4. Editorial: Mechanisms Underlying Diabetes-Associated Damage in Target Tissues

    Frontiers in Pharmacology

  5. Epigenetic Modulation of Gremlin-1/NOTCH Pathway in Experimental Crescentic Immune-Mediated Glomerulonephritis

    Pharmaceuticals, Vol. 15, Núm. 2

  6. Epigenetic networks driving T cell identity and plasticity during immunosenescence

    Trends in Genetics

  7. Kidney microRNA Expression Pattern in Type 2 Diabetic Nephropathy in BTBR Ob/Ob Mice

    Frontiers in Pharmacology, Vol. 13

  8. The CCN2 Polymorphism rs12526196 Is a Risk Factor for Ascending Thoracic Aortic Aneurysm

    International Journal of Molecular Sciences, Vol. 23, Núm. 23

2021

  1. An epigenetic insight into NLRP3 inflammasome activation in inflammation-related processes

    Biomedicines, Vol. 9, Núm. 11

  2. Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia

    OncoImmunology, Vol. 10, Núm. 1

  3. Correction to: Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS‑CoV‑2 infectivity (Clinical Epigenetics, (2021), 13, 1, (187), 10.1186/s13148-021-01168-5)

    Clinical Epigenetics

  4. Defining a Methylation Signature Associated With Operational Tolerance in Kidney Transplant Recipients

    Frontiers in Immunology, Vol. 12

  5. Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity

    Clinical Epigenetics, Vol. 13, Núm. 1

  6. Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity

    International Immunopharmacology, Vol. 98

2019

  1. Acute myeloid leukemia and NK cells: two warriors confront each other

    OncoImmunology, Vol. 8, Núm. 2